At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 22 enrolled
Drug / intervention
[12C] RO7049389 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-Label Study to Investigate the Mass Balance and Absolute Bioavailability of a Single Oral Dose of [14C]-Labeled RO7049389 or RO7049389 and an Intravenous Micro-Dose of [13C]-Labeled RO7049389 in Healthy Volunteers
In Brief
A Phase 1 clinical trial evaluating [12C] RO7049389, [13C] RO7049389, and 1 other intervention for Healthy Volunteers. Completed, enrolled 22 participants across 1 site.
Detailed Summary
The objective of this study is to characterize the mass balance, absolute bioavailability, route and rates of elimination of RO7049839.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedJan 2021
Enrollment StartMar 2021
Primary CompletionJun 2021
TodayJul 2026
First PostedJan 28, 2021
Enrollment StartMar 31, 2021
Primary CompletionJun 14, 2021
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 5.4 years ago
Interventions
[12C] RO7049389drug
Participants will receive oral \[12C\] RO7049389.
[13C] RO7049389drug
Participants will receive IV \[13C\] RO7049389.
[14C] RO7049389drug
Participants will receive an oral suspension of \[14C\] RO7049389.